Improved detection of the MUC1 cancer antigen CA 15-3 by ALYGNSA fluorimmunoassay
Date
2011-08-11
Journal Title
Journal ISSN
Volume Title
Publisher
Health
Abstract
Breast cancer is the second leading cause of cancer-related deaths in women worldwide; a prime cancer biomarker to aid in the diagnosis, directed treatment, clinical management, and reoccurrence of this cancer is a MUC1 peptide fragment: cancer antigen 15-3 (CA 15-3). Herein, an immuno-fluorescence assay for CA 15-3 was developed; this ALYGNSA system consists of a protein biolinker (Protein G’) adsorbed onto Poly (methyl methacrylate) (PMMA). The unique interaction of Protein G’ with PMMA, a thermo- plastic polymer has been demonstrated to im- prove human IgG capture antibody alignment/ orientation and result in greater assay sensi- tivity. Indeed a previous report (HEALTH 1 325 - 329, 2009) on the shed extracellular domain of HER-2/neu revealed a 10-fold increase in sensi- tivity of the ALYGSNA assay over a control ELISA assay. Results from this ALYGNSA assay study revealed that a 16-fold increase in dete- ction (?0.94 U/mL) of CA 15-3 was found in comparison to a commercial control ELISA kit (?15 U/mL). In conclusion, this enhanced sen- sitivity of the ALYGNSA assay for CA 15-3, may provide insights into the role/function of this biomarker in normal, as well as, breast cancer and other epithelial cancers.
Description
Melisenda McDonald and Leslie R. Farris serve on the faculty at UMass Lowell in the Department of Chemistry.
item.page.type
Article
item.page.format
Keywords
Citation
Chourb, S., Mackness, B. C., Farris, L. R., McDonald, M. J. (2011, August 11). Improved detection of the MUC1 cancer antigen CA 15-3 by ALYGNSA fluorimmunoassay. Health 3(8), 524-528. http://www.scirp.org/journal/PaperInformation.aspx?PaperID=6786